Crown Bioscience has completed a joint study with CARsgen Therapeutics and Shanghai Cancer Institute, demonstrating the elimination of gastric tumors in mice using CLDN18.2 targeting CAR-T cells. The work was recently published in the Journal of the National Cancer Institute.
CAR-T cells were engineered to target Claudin18.2 and tested in gastric adenocarcinoma PDX models expressing high levels of Claudin 18.2.
“Humanized antibodies were developed and tested for their ability to redirect CAR-T cells on our PDX models. Tumor elimination was observed with no deleterious effect on normal gastric tissue in the mice, further validating it as high value CAR-T target and demonstrating a promising result for gastric and other CLDN18.2 positive tumors,” said Henry Li, a co-author on the paper and senior vice president of research and innovation at Crown Bioscience.
A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement.